Down Syndrome: Clinical Case Discussion & Key Points
Model Case Presentation
Patient Demographics
Name: Master Arjun, Age: 6 months, Gender: Male, Informant: Mother (Reliable)
Chief Complaints
- Dysmorphic facial features noted since birth
- Poor weight gain and developmental delay – 6 months
- Feeding difficulty since birth
- Fast breathing – 2 months
History Summary
Baby was born at term via LSCS. At birth, the attending pediatrician noted upslanting palpebral fissures, flat face, protruding tongue, hypotonia and referred for further evaluation. Mother is 38 years old (elderly primigravida). Antenatal period: no anomaly scan done; no folic acid supplementation before conception. Birth weight 2.6 kg. Neonatal period: poor cry, poor suck, significant jaundice requiring phototherapy for 5 days.
Current developmental history: no social smile by 3 months (achieved at 5 months), not holding head steadily at 6 months, not reaching for objects. Feeding is difficult — takes long to complete feeds, tires easily (suck-rest-suck pattern), sweats during feeds.
Two episodes of respiratory infections in 4 months requiring hospitalization. No cyanosis, no squatting, no seizures. Non-consanguineous marriage. No family history of similar condition or chromosomal abnormality.
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Weight | 5.2 kg | Below 3rd centile (expected ~7.3 kg) — Failure to Thrive |
| Length | 60 cm | Below 3rd centile — Short stature |
| Head Circumference | 38 cm | Microbrachycephaly |
| RR | 58/min | Tachypnea (CHD with heart failure) |
| HR | 148/min | Tachycardia |
| SpO2 | 97% | Adequate oxygenation |
| Temperature | 37°C | Afebrile |
| Tone | Hypotonia | Characteristic of Down syndrome |
Dysmorphic Features
| Region | Findings |
|---|---|
| Face | Flat facies, flat nasal bridge, flat occiput (brachycephaly) |
| Eyes | Upslanting palpebral fissures, bilateral epicanthal folds, Brushfield spots |
| Ears | Small, low-set with overfolded upper helix |
| Mouth | Open mouth, protruding tongue (relative macroglossia), high arched palate |
| Neck | Short, with excess nuchal skin |
| Hands | Short broad hands, clinodactyly of 5th finger, single transverse palmar crease (bilateral) |
| Feet | Wide sandal gap (between 1st and 2nd toe), plantar crease |
| Abdomen | Umbilical hernia, mild hepatomegaly |
Cardiovascular: Hyperdynamic precordium. Loud, harsh pansystolic murmur at left lower sternal border, Grade 4/6. Mid-diastolic murmur at apex (flow murmur). Loud P2. Hepatomegaly 3 cm below RCM. Bilateral basal crepitations.
Neurological: Global hypotonia. Absent Moro reflex. Delayed developmental milestones.
✅ Complete Diagnosis
Down Syndrome (Trisomy 21) — Complete (Non-Disjunction Type) with Large Atrioventricular Septal Defect (AVSD) in Congestive Heart Failure, with Failure to Thrive and Global Developmental Delay.
📝 History — Exam Q&A
Down syndrome (Trisomy 21) is the most common chromosomal aneuploidy in live-born humans, caused by the presence of an extra chromosome 21 (47 chromosomes total). It is characterized by intellectual disability, dysmorphic features, and multiple systemic associations.
Incidence: ~1 in 700–1000 live births overall. With maternal age 20 years: 1 in 1449; at 35 years: 1 in 385; at 40 years: ~1 in 100; at 45 years: ~1 in 26.
| Type | Mechanism | Karyotype | Frequency | Recurrence Risk |
|---|---|---|---|---|
| Non-disjunction (Free trisomy 21) | Failure of chr. 21 to separate during meiosis (usually meiosis I, maternal) | 47,XX/XY,+21 | ~94% | ~1% above age-related risk |
| Robertsonian Translocation | Chr. 21 attached to another chr., usually chr. 14 — t(14;21) | 46 chromosomes (with extra 21 material) | ~3–4% | High — up to 100% if carrier parent |
| Mosaicism | Non-disjunction after fertilization; mixture of normal (46) and trisomic (47) cells | 47,+21 / 46 (mosaic) | ~2–3% | Low |
💡 Key Exam Point
Translocation Down syndrome is the only inherited form. A balanced translocation carrier parent (karyotype 45 chromosomes) can pass it on. Recurrence risk: if mother is carrier ~10–15%, if father is carrier ~5%. This is why parental karyotyping is mandatory in translocation DS — not in non-disjunction.
Oocytes are arrested in meiosis I (prophase I) from fetal life. In older women, oocytes have been arrested longer, leading to deterioration of the spindle apparatus and cohesin proteins that hold sister chromatids together. This increases the risk of non-disjunction during meiosis I, resulting in an egg with two copies of chromosome 21. Maternal origin accounts for ~95% of non-disjunction cases.
Note: Maternal age effect applies only to non-disjunction type, NOT to translocation type.
- Dysmorphic facial features apparent at birth (flat face, upslanting eyes, protruding tongue)
- Hypotonia — "floppy baby", poor Moro reflex
- Feeding difficulty (poor suck due to hypotonia + macroglossia)
- Prolonged neonatal jaundice
- Global developmental delay (motor, speech, cognitive)
- Failure to thrive
- Features of associated CHD (tachypnea, tachycardia, murmur)
- Recurrent respiratory infections
- Maternal age — advanced age (≥35 years) is the most important risk factor
- Prenatal screening done? — Double marker, Triple marker, Quadruple marker, NT scan, NIPT (cfDNA)
- Prenatal diagnosis? — Amniocentesis, CVS (chorionic villus sampling)
- Fetal anomaly scan findings — increased nuchal translucency, absent nasal bone, AV canal defect, duodenal atresia ("double bubble"), echogenic bowel
- Previous child with Down syndrome — raises possibility of parental translocation
- Family history of chromosomal abnormalities or recurrent abortions
- Consanguinity — though less relevant for DS, rules out other genetic conditions
| System | Association | Frequency / Note |
|---|---|---|
| Cardiovascular | AVSD (most common in Western literature), VSD, ASD, PDA, TOF | ~40–50% of DS |
| GI | Duodenal atresia ("double bubble"), Hirschsprung disease, Tracheo-oesophageal fistula, Imperforate anus, Annular pancreas | ~5–10% |
| Haematological | Transient Abnormal Myelopoiesis (TAM), AML (AMKL), ALL | TAM ~10–30% neonates |
| Thyroid | Hypothyroidism (autoimmune), rarely hyperthyroidism | ~15–20% |
| ENT / Auditory | Recurrent otitis media, conductive and sensorineural hearing loss | ~66% |
| Ophthalmological | Refractive errors, strabismus, nystagmus, cataracts, Brushfield spots | ~50–70% |
| Orthopaedic | Atlantoaxial instability, hip dislocation, pes planus, scoliosis | ~10–30% |
| Neurological | Intellectual disability, seizures (infantile spasms), Alzheimer disease in adults | Alzheimer's ~50% by 50–60 yrs |
| Endocrine | Diabetes mellitus, obesity, growth hormone deficiency | Increased risk |
| Respiratory | Obstructive sleep apnea, recurrent pneumonias, pulmonary hypertension | ~50–75% OSA |
In the first two years of life: Congenital heart disease (particularly AVSD with pulmonary hypertension) is the leading cause of early mortality.
In adults (after CHD is corrected): Alzheimer's disease and its complications. Almost all individuals with DS develop Alzheimer neuropathology by age 40, and ~50% develop clinical Alzheimer's disease by the 5th–6th decade.
All domains of development are affected, but at varying degrees. Motor milestones are typically delayed by 2–3× normal. Cognitive delay ranges from mild to moderate intellectual disability (IQ typically 35–70). Speech and language delay is often more pronounced than motor delay.
| Milestone | Normal Age | Typical DS |
|---|---|---|
| Social smile | 6 weeks | 2–3 months |
| Head control | 4 months | 6–9 months |
| Sitting unsupported | 6 months | 11 months |
| Walking | 12–15 months | 19–24 months |
| First words | 12 months | 18–24 months |
| Two-word sentences | 18–24 months | 3–4 years |
Depends on the type:
- Non-disjunction (94%): Empirical risk is approximately 1% + age-related risk. For mothers under 30 years: ~1%. For mothers over 35: age-related risk dominates.
- Translocation (3–4%):
- If mother is balanced translocation carrier t(14;21): ~10–15% recurrence risk
- If father is balanced translocation carrier: ~5% recurrence risk
- If translocation is de novo (not inherited from parent): ~1–2%
- Mosaicism (2%): Low empirical recurrence risk; parental karyotyping recommended to rule out parental mosaicism.
🚨 Key Practice Point
Parental karyotyping is indicated in all cases of translocation Down syndrome to identify balanced translocation carrier parents, who carry a significantly elevated recurrence risk. It is NOT routinely indicated in non-disjunction type.
The clinical syndrome was described by John Langdon Down in 1866. In 1959, Jérôme Lejeune (along with Marthe Gauthier and Raymond Turpin) discovered that Down syndrome is caused by an extra chromosome 21 (trisomy 21), establishing it as the first chromosomal disorder identified in humans.
🩺 Examination — Exam Q&A
- Flat facies — flat face overall (most striking feature)
- Brachycephaly — short head with flat occiput
- Upslanting palpebral fissures (vs downslanting in Turner, Noonan)
- Bilateral epicanthal folds — inner corner skin folds
- Brushfield spots — white/grey speckles around the periphery of the iris (seen in light-coloured eyes)
- Depressed (flat) nasal bridge
- Small, low-set ears with overfolded upper helix
- Open mouth with protruding tongue — due to relative macroglossia and hypotonia
- High arched palate
- Furrowed/geographic tongue
- Short, broad neck with excess nuchal skin
Hands:
- Short, broad hands ("trident hand")
- Single transverse palmar crease (simian crease) — present in ~45–60% of DS patients (also seen in 1–4% of normal population)
- Clinodactyly of 5th finger — inward curvature
- Hypoplasia of the middle phalanx of the 5th finger (brachymesophalangy)
- Single flexion crease on 5th finger
- Distal palmar axial triradius (~84%)
- Ulnar loops on all fingertips (dermatoglyphics)
Feet:
- Wide "sandal gap" — increased gap between 1st and 2nd toe
- Plantar crease between 1st and 2nd toe
- Short, stubby toes
Hypotonia (low muscle tone) is present in virtually all newborns with DS. It is central (neurological) in origin rather than neuromuscular. Consequences include:
- Poor suck reflex → feeding difficulties → failure to thrive
- Delayed gross motor milestones
- Absent or weak Moro reflex at birth
- Open mouth posture, protruding tongue
- Joint hypermobility and ligamentous laxity → risk of atlantoaxial instability
- Constipation (hypotonic bowel)
- Obstructive sleep apnea (hypotonic pharyngeal muscles)
AVSD (Atrioventricular Septal Defect) = Endocardial cushion defect = AV canal defect — the most characteristic cardiac defect of Down syndrome in Western literature (~40–50% of DS-CHD).
Complete AVSD findings:
- Prominent left precordium with hyperdynamic apex
- Systolic thrill at left lower sternal border
- Grade 4/6 pansystolic murmur at LLSB (VSD component)
- Mid-diastolic murmur at apex (large shunt flow murmur)
- Loud P2 (pulmonary hypertension)
- Signs of CCF: tachypnea, hepatomegaly, tachycardia, crepitations
💡 DS + AVSD Specifics
DS patients develop pulmonary arterial hypertension earlier and more severely than non-DS patients with equivalent cardiac defects. Eisenmenger syndrome can develop by 1–2 years of age if uncorrected. Early surgical repair (within 3–6 months) is therefore critical.
Brushfield spots are white or light grey speckles arranged in a ring near the periphery of the iris, representing focal areas of iris stromal hypoplasia surrounded by areas of relative hypoplasia.
They are present in ~75–85% of Down syndrome patients with light-coloured eyes, and in ~7–20% of normal individuals. They are therefore NOT pathognomonic of Down syndrome — they are a supportive finding, not diagnostic.
Due to ligamentous laxity (particularly laxity of the transverse ligament of the atlas), there is abnormal mobility between C1 (atlas) and C2 (axis) vertebrae. AAI is present in ~10–30% of DS patients.
Significance: Excessive neck extension or flexion can cause compression of the spinal cord. Risk especially during anesthesia, contact sports, or trampoline activities.
Screening: Lateral cervical X-ray in flexion, neutral, and extension positions. Atlanto-dens interval (ADI) > 5 mm is considered abnormal in children.
Symptoms of cord compression: neck pain, torticollis, weakness, gait change, bladder/bowel dysfunction, hyperreflexia.
🚨 Clinical Alert
All children with DS should be screened for AAI before participating in contact sports or high-risk activities (e.g., gymnastics, diving, Special Olympics). Anesthesiologists must take precautions during intubation.
- Umbilical hernia — common (~30%); usually closes spontaneously
- Diastasis recti
- Signs of duodenal atresia (in neonates) — bilious vomiting, distended upper abdomen
- Signs of Hirschsprung disease — constipation, distended abdomen, empty rectum on PR exam
- Hepatomegaly in TAM/leukemia or CCF
| Syndrome | Palpebral Fissure Direction |
|---|---|
| Down syndrome (Trisomy 21) | Upslanting (lateral angle higher than medial) |
| Turner syndrome (45,X) | Downslanting |
| Noonan syndrome | Downslanting, widely spaced |
| Treacher Collins syndrome | Downslanting |
| Normal | Horizontal (lateral angle slightly lower) |
🔬 Investigations — Exam Q&A
Karyotyping (cytogenetic analysis) on a peripheral blood sample is the gold standard. It confirms:
- The type: non-disjunction (47,XX/XY,+21), translocation, or mosaicism
- Whether translocation is de novo or inherited (crucial for genetic counseling)
FISH (Fluorescence In Situ Hybridization): Rapid test (24–48 hours) — confirms extra chromosome 21 but cannot identify translocations. A positive FISH must always be confirmed by full karyotype.
QF-PCR (Quantitative Fluorescent PCR): Another rapid molecular method — detects extra chromosome 21 quickly, useful for urgent postnatal diagnosis.
| Test | Trimester | Markers / Method | Note |
|---|---|---|---|
| Double Marker Test | 1st (11–13+6 wks) | PAPP-A (↓), free β-hCG (↑) + NT scan | Screening only; combined with NT = ~85–90% detection |
| Triple Marker Test | 2nd (15–20 wks) | AFP (↓), β-hCG (↑), uE3 (↓) | ~70% detection; less sensitive |
| Quadruple Marker Test | 2nd (15–20 wks) | AFP ↓, β-hCG ↑, uE3 ↓, Inhibin A ↑ | ~80% detection |
| NT (Nuchal Translucency) Scan | 1st (11–14 wks) | Increased nuchal translucency (>3 mm) | Imaging marker; also detects other anomalies |
| Cell-free DNA (cfDNA / NIPT) | From 9–10 wks | Placental DNA in maternal blood | Most sensitive: detection rate ~99.7%, FPR 0.04%. Screening, NOT diagnostic |
| Amniocentesis | 2nd (15–20 wks) | Fetal amniocytes → karyotype | Diagnostic; risk of miscarriage ~0.5% |
| CVS (Chorionic Villus Sampling) | 1st (10–13 wks) | Chorionic villi → karyotype | Diagnostic; earlier result; risk ~1% |
💡 Mnemonic for Triple Marker
In Down syndrome: AFP ↓, β-hCG ↑, uE3 ↓ — Remember "Down goes Down" (AFP and uE3 go down), hCG goes Up.
Major markers:
- Increased nuchal translucency (>3 mm at 11–14 weeks)
- Absent/hypoplastic nasal bone
- AVSD / atrioventricular canal defect
- Duodenal atresia — "double bubble sign"
Minor markers (soft markers):
- Echogenic bowel
- Short femur and humerus
- Mild renal pyelectasis
- Echogenic intracardiac focus (EIF)
- Widened nuchal fold (>6 mm) in 2nd trimester
- Sandal gap (wide space between 1st and 2nd toes) — detectable by fetal US
At birth / neonatal period:
- Karyotype (confirm diagnosis and type)
- Echocardiogram — all DS infants, even if asymptomatic (40–50% have CHD)
- Thyroid function tests (TSH) at day 7, then annually
- CBC — to rule out TAM / polycythemia
- Hearing screening (BERA/OAE)
- Ophthalmology evaluation (red reflex — cataracts)
At 6 months: Developmental assessment, repeat TFT, hearing, ophthalmology
At 2–3 years: Cervical spine X-ray (to screen for AAI), sleep study if OSA suspected
Annually: TFT, CBC, hearing, vision, growth monitoring on DS-specific growth charts
ECG in Complete AVSD:
- Superior QRS axis (left axis deviation / "northwest axis" — characteristic) due to the abnormal conduction through the hypoplastic AV node
- First degree AV block (prolonged PR interval)
- Biventricular hypertrophy (tall R in V5, tall R in V1)
- Left atrial enlargement (broad P waves)
Superior (leftward/northwest) axis on ECG in AVSD is a classic exam question — caused by hypoplasia of the posteroinferior division of the left bundle and the AV node displacement. It produces a counterclockwise frontal loop → left axis deviation even in infancy.
CXR in AVSD:
- Cardiomegaly (increased CT ratio)
- Biventricular and LA enlargement
- Prominent main pulmonary artery
- Pulmonary plethora — increased pulmonary vascular markings
1. Polycythemia — common in neonates with DS; may contribute to poor feeding, jaundice, and thrombocytosis.
2. Transient Abnormal Myelopoiesis (TAM) — previously called Transient Myeloproliferative Disorder (TMD):
- Occurs in ~10% (possibly up to 30% subclinically) of DS neonates
- Due to somatic GATA1 mutation in fetal hematopoietic cells
- Clinically: blasts in peripheral blood, hepatosplenomegaly, skin lesions
- Usually resolves spontaneously within 3 months
- ~20–30% progress to frank Myeloid Leukemia of Down Syndrome (ML-DS) within 1–4 years
3. Myeloid Leukemia of Down Syndrome (ML-DS):
- Acute Megakaryoblastic Leukemia (AMKL/FAB M7) — 500-fold increased risk vs non-DS
- Highly chemo-sensitive; EFS ~80% (paradoxically better than non-DS AML)
4. Acute Lymphoblastic Leukemia (ALL):
- ~20-fold increased risk; typically B-cell ALL
- Less favorable prognosis than non-DS ALL; more chemo toxicity
Hypothyroidism is the most common thyroid disorder, occurring in ~15–20% of DS children. It is usually autoimmune (Hashimoto's thyroiditis). May also be congenital (due to thyroid dysgenesis).
Rarely: Hyperthyroidism (Graves' disease) can also occur.
Screening protocol (per AAP 2022): TSH at birth (newborn screen), at 6 months, 12 months, and then annually throughout life. Free T4 should be added if TSH is abnormal.
Why important: Untreated hypothyroidism worsens developmental outcomes and can mimic or exacerbate features of DS (increased hypotonia, weight gain, developmental regression).
The "double bubble" sign on abdominal X-ray (or prenatal ultrasound) represents two gas-filled bubbles — the stomach and the proximal duodenum — separated by the pylorus, with no gas beyond. This is the classic finding in duodenal atresia or stenosis.
Association with DS: ~30% of duodenal atresia cases are associated with Down syndrome. Conversely, ~5% of DS patients have duodenal atresia. It is the most common GI surgical emergency in DS newborns.
Management: Surgical — duodenoduodenostomy (bypassing the atretic segment).
💊 Management — Exam Q&A
Management is multidisciplinary and lifelong. There is no cure for the chromosomal abnormality. Goals are to maximize the child's developmental potential, treat associated conditions, and support the family.
- Genetic counseling — explain diagnosis, type, recurrence risk, prognosis to family
- Cardiac evaluation — echo within first month of life; early surgical repair of CHD
- Early intervention therapies — physical therapy, occupational therapy, speech therapy (started as early as possible)
- Medical treatment of associated conditions (hypothyroidism, infections, celiac disease)
- Nutritional support — high-calorie feeds if CHD/FTT; nasogastric tube if needed
- Surgical management — CHD, duodenal atresia, Hirschsprung disease, cataract, others
- Surveillance — regular monitoring per AAP Down syndrome health supervision guidelines
- Education — special education, inclusive schooling, life skills training
- Parent support groups and community resources
Medical management (before surgery):
- Diuretics: Furosemide + Spironolactone (decongest lungs)
- ACE inhibitors: Enalapril/Captopril (reduce afterload, decrease L→R shunt)
- Digoxin: mild inotropic support
- High-calorie feeds / NG tube — to optimize nutrition for surgery
- Treat infections promptly
Surgical management:
- Complete AVSD repair — single-patch or two-patch technique under cardiopulmonary bypass
- Timing: Within 3–6 months of age (before irreversible pulmonary hypertension develops)
- DS patients develop PAH earlier and faster than non-DS; the "window of operability" is shorter
- Post-operative outcomes are generally favorable — mortality risk comparable to non-DS for complete AVSD repair
🚨 Contraindication
Once Eisenmenger syndrome develops (irreversible PAH with shunt reversal → cyanosis), surgical closure is contraindicated. Medical management with pulmonary vasodilators (sildenafil, bosentan) may help symptoms. Only heart-lung transplant is curative.
- Early Intervention Program — ideally started within first few months of life. Evidence shows that early stimulation significantly improves cognitive and motor outcomes.
- Physical Therapy (PT) — improves muscle tone, motor development, coordination
- Occupational Therapy (OT) — fine motor skills, ADLs, sensory processing
- Speech and Language Therapy (SLT) — most critical; language is the most affected domain; also addresses feeding difficulties
- Behavioral therapy — for ASD features if present
- Special education — individualized education programs (IEP); many DS children can achieve functional literacy
- Adults: supported employment, semi-independent living programs
Most cases of TAM (resolve spontaneously within 2–3 months). Management:
- Close monitoring with CBC and blood film
- Supportive care: treat complications (hepatic dysfunction, coagulopathy, effusions)
- Low-dose cytarabine may be used in severe symptomatic TAM (e.g., hydrops, severe liver disease, high WBC >100,000/µL)
- Screen for GATA1 mutation — all DS neonates with TAM should have GATA1 tested
- Long-term surveillance — CBC every 3–6 months for 3 years, as 20–30% develop ML-DS
Most DS patients with AAI are asymptomatic and are managed conservatively (activity restriction, no contact sports, anesthetic precautions).
Surgical stabilization (C1-C2 fusion) is indicated when:
- Symptomatic cord compression (weakness, bowel/bladder dysfunction, hyperreflexia)
- ADI > 10 mm on X-ray (very high instability)
- Progressive symptoms despite conservative management
Note: Asymptomatic AAI with ADI 5–10 mm — activity restriction + 6-monthly surveillance; prophylactic fusion is NOT routinely recommended for asymptomatic AAI.
Children with DS are shorter than average due to reduced GH secretion and GH insensitivity. Growth hormone therapy has been studied in DS:
- Can improve short-term linear growth velocity
- Some studies show modest improvement in motor development and cognitive scores
- However, evidence is insufficient for routine use
- Not currently recommended as standard treatment
- DS-specific growth charts (not standard WHO charts) should be used for monitoring
DS children are immunocompromised (reduced T-cell function, impaired antibody responses) and are at higher risk of severe infections. In addition to the routine immunization schedule, the following are recommended:
- Influenza vaccine — annually
- Pneumococcal vaccine — both PCV13 and PPSV23 (high risk group)
- Hepatitis A and B vaccines — per schedule
- RSV prophylaxis (Palivizumab) — if significant CHD
🔭 Recent Advances — Exam Q&A
NIPT uses cell-free fetal/placental DNA (cfDNA) circulating in maternal blood to screen for chromosomal aneuploidies, including trisomy 21.
- Can be done from 9–10 weeks gestation onward
- Detection rate for Down syndrome: ~99.7%
- False positive rate: ~0.04% — far superior to conventional serum markers
- It is a SCREENING test — a high-risk result must be confirmed by invasive diagnostic testing (amniocentesis/CVS + karyotype)
- Can simultaneously screen for trisomy 18, 13, and sex chromosome aneuploidies
- Now offered to all pregnant women in many countries, not just high-risk
GATA1 is a transcription factor essential for normal megakaryocyte and erythroid development.
In DS, the combination of constitutional trisomy 21 (first hit) + somatic GATA1 mutation in exon 2 (second hit, occurring in utero) leads to translation of a shorter isoform called GATA1s. This truncated protein loses its N-terminal transactivation domain and cannot properly regulate megakaryocyte differentiation.
Consequence: GATA1 mutation → TAM in neonates. Additional mutations in cohesin genes, RAS pathway genes → progression to ML-DS (AMKL).
This well-characterized multi-step leukemogenesis pathway makes DS-leukemia a valuable model for understanding cancer biology in general.
Several pathways are being investigated:
- DYRK1A inhibition — DYRK1A gene on chromosome 21 is overexpressed; its inhibition in mouse models improves learning and memory. Clinical trials ongoing.
- APP (Amyloid Precursor Protein) — overexpressed in DS, leading to amyloid-β accumulation. Anti-amyloid therapies (e.g., lecanemab) are being trialed in DS-associated Alzheimer disease.
- GABAA receptor modulation — cognitive deficits are partly due to excessive GABAergic inhibition; clinical trials with GABA antagonists (e.g., basmisanil) showed limited benefit in early trials.
- GnRH (Gonadotropin-releasing hormone) therapy — French trial showed cognitive improvements in DS males treated with pulsatile GnRH; mechanism involves olfactory bulb and hippocampal pathways.
- Chromosome silencing therapy (XIST gene-based approaches) — experimental; aims to silence the extra chromosome 21.
The APP (Amyloid Precursor Protein) gene is located on chromosome 21. Trisomy 21 leads to a 50% increase in APP expression → excess amyloid-β production → amyloid plaques + neurofibrillary tangles (same neuropathology as Alzheimer's).
- Almost all DS individuals show Alzheimer neuropathology by age 40 years
- Clinical Alzheimer's disease develops in ~50% by age 50–60 years and >90% by the 7th decade
- Earlier age of onset than sporadic AD
- Down syndrome is the largest genetically defined risk group for Alzheimer's disease
Anti-amyloid and anti-tau therapies being trialed specifically in DS Alzheimer cohorts (Down Syndrome Biomarker Initiative — DSBI).
Mosaic trisomy 21 occurs when a non-disjunction error happens after fertilization, resulting in two cell populations: 46-chromosome (normal) and 47-chromosome (trisomic) cells.
- Generally milder phenotype — less severe dysmorphism and higher IQ (mean IQ ~10–30 points higher than complete trisomy 21)
- However, clinical features can range from indistinguishable from complete trisomy 21 to very subtle
- Diagnosis can be missed — requires peripheral blood karyotype with sufficient cells counted (≥30 cells)
- Recurrence risk is low; parental karyotype should still be done to exclude parental mosaicism
- Prognosis cannot be precisely predicted from the proportion of trisomic cells in blood, as it varies by tissue
⚡ Key Points — Quick Revision
One-Liners for Exam — Genetics
- Most common aneuploidy in live births: Trisomy 21 (Down syndrome)
- Incidence: ~1 in 700 live births
- Most common type: Non-disjunction (94%) — usually maternal meiosis I error
- Inherited type: Robertsonian translocation only (parental karyotype mandatory)
- Maternal age: Risk factor for non-disjunction, NOT translocation
- Gold standard diagnosis: Karyotype
- Most sensitive prenatal screen: cfDNA/NIPT (99.7% detection) — screening, not diagnostic
- Diagnostic tests: Amniocentesis (2nd trimester), CVS (1st trimester)
- Triple marker in DS: AFP ↓, β-hCG ↑, uE3 ↓
- Antenatal US markers: Increased NT, absent nasal bone, AVSD, double bubble sign
One-Liners for Exam — Clinical Features
- Pathognomonic finding: None — diagnosis is clinical + karyotype
- Most consistent finding: Flat facies + hypotonia + upslanting palpebral fissures
- Eye finding: Brushfield spots (not pathognomonic — seen in normals too)
- Palpebral fissure: Upslanting (vs downslanting in Turner/Noonan/Treacher Collins)
- Palmar crease: Single transverse palmar crease (simian crease) — ~45–60% DS
- Foot finding: Wide sandal gap (wide 1st–2nd toe space)
- Hand: Clinodactyly of 5th finger, short broad hands
- Cardiac defect: AVSD (most common in Western literature); VSD also common
- GI emergency in neonates: Duodenal atresia ("double bubble" sign)
- Atlantoaxial instability: Present in ~10–30%; risk of cord compression
One-Liners for Exam — Associations & Management
- Leading cause of death in early life: CHD (AVSD with PAH)
- Cause of death in adults: Alzheimer's disease
- Leukemia risk: AML (500×), ALL (20×) increased vs general population
- TAM: ~10–30% DS neonates; due to GATA1 mutation; usually resolves spontaneously
- TAM → ML-DS: ~20–30% of TAM cases progress to AMKL within 1–4 years
- DS AML is paradoxically chemo-sensitive: EFS ~80% (better than non-DS AML)
- Thyroid: ~15–20% hypothyroidism; screen TSH annually
- Alzheimer's: APP gene on chr. 21 overexpressed → amyloid excess; >90% by 7th decade
- Cardiac surgery timing (AVSD): Within 3–6 months — PAH develops faster in DS
- Parental karyotype required: Only in translocation type, not non-disjunction
- Mosaic DS: Milder features, higher IQ; diagnosis can be missed
- Routine echo: All DS infants even if no murmur heard
📌 Mnemonic — Features of Down Syndrome: "FLATTENED"
- F — Flat face, Flat nasal bridge
- L — Low-set ears, Ligamentous laxity (AAI)
- A — Atlantoaxial instability, AVSD (cardiac)
- T — Tongue protruding (macroglossia), Thyroid (hypothyroidism)
- T — Trisomy 21, Transient Abnormal Myelopoiesis
- E — Epicanthal folds, Ears (hearing loss)
- N — Neck excess skin, Neurological (intellectual disability)
- E — Eyes upslanting, Ear infections (otitis media)
- D — Duodenal atresia, Developmental delay